You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2012
|
| DOI | 10.3389/fphar.2012.00152 |
| Pubmed ID | |
| Authors |
E. W. Chua, M. A. Kennedy |
| Abstract |
Direct-to-consumer (DTC) DNA testing has grown from contentious beginnings into a global industry, by providing a wide range of personal genomic information directly to its clients. These companies, typified by the well-established 23andMe, generally carry out a gene-chip analysis of single-nucleotide polymorphisms (SNPs) using DNA extracted from a saliva sample. These genetic data are then assimilated and provided direct to the client, with varying degrees of interpretation. Although much debate has focused on the limitations and ethical aspects of providing genotypes for disease risk alleles, the provision of pharmacogenetic results by DTC companies is less studied. We set out to evaluate current DTC pharmacogenetics offerings, and then to consider how these services might best evolve and adapt in order to play a potentially useful future role in delivery of personalized medicine. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Netherlands | 1 | 1% |
| United States | 1 | 1% |
| South Africa | 1 | 1% |
| Unknown | 72 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 17% |
| Student > Bachelor | 13 | 17% |
| Researcher | 10 | 13% |
| Student > Ph. D. Student | 9 | 12% |
| Student > Postgraduate | 6 | 8% |
| Other | 11 | 14% |
| Unknown | 14 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 19 | 25% |
| Medicine and Dentistry | 15 | 20% |
| Biochemistry, Genetics and Molecular Biology | 9 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 9 | 12% |
| Unknown | 17 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2013.
All research outputs
#3,645,134
of 22,675,759 outputs
Outputs from Frontiers in Pharmacology
#1,544
of 15,845 outputs
Outputs of similar age
#30,934
of 244,088 outputs
Outputs of similar age from Frontiers in Pharmacology
#22
of 137 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 15,845 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,088 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.